SynthesisArchives of dermatological research2025
Efficacy and safety of Kangfuxin liquid for eczema: a systematic review and meta-analysis.
Synthesis in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical evidence on integrated Chinese-Western medicine for atopic dermatitis.Integrative medicine research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Eczema is a chronic, recurrent dermatosis with the skin repeated inflammation, itching, red and swollen. Such experience often take a physical and mental double burden on patients and their caregivers and family member. At present, the existing treatment methods have different limitations. In China, Kangfuxin liquid has been clinically used to treat eczema, and has shown good therapeutic effect. In order to conduct a more comprehensive analysis of clinical data and bring more references for clinicians and experts, this paper adopted a systematic review and meta-analysis to evaluate the effectiveness of Kangfuxin liquid in the treatment of eczema. We conducted a search in several databases, including EMBASE, PubMed, and the Cochrane Library, to identify suitable randomized controlled trials (RCTs). Following this, we gathered data from the RCTs which compared conventional therapies to Kangfuxin liquid alone or in combination with conventional therapies. We utilized RevMan 5.4 software to compute 95% confidence intervals (CIs) and risk ratios (RRs), and to carry out the meta-analysis. 17 meta-analyses involving 1725 patients were included. A meta-analysis showed that standalone Kangfuxin liquid therapy significantly improved the overall effective rate compared to nonglucocorticoid ointment therapy (Kangfuxin liquid vs nonglucocorticoid ointment: RR, 1.24; 95% CI, 1.09-1.42; P = 0.001). The total effective rate for standalone Kangfuxin liquid therapy was consistent with that of glucocorticoid ointment therapy (Kangfuxin liquid vs glucocorticoid ointment: RR, 1.09; 95% CI, 0.88-1.36; P = 0.41). In addition, the results were significantly improved when Kangfuxin liquid combined with conventional western medicine (Kangfuxin liquid + conventional Western medicine vs conventional Western medicine: RR, 1.12; 95% CI, 1.03-1.22; P = 0.009). Kangfuxin liquid can effectively treat eczema. However, further scale-up, involving more rigorous, precise, and inclusive meta-analyses are needed to make a significant difference in the treatment of eczema.
Indexed as
Identifiers
40111524What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.